PTC Therapeutics, Inc.

PTCT Healthcare Biotechnology

PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

59.24 1.75 −2.87%
Market cap
$5.1B
P/E
0.0×
Fwd P/E
110×
Dividend yield
—
F-score
7/9
Altman Z
1.86
Beneish M
−1.48
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 8.64 6.39

+8 more quarters

P/S ratio
6.71 6.80 3.49 2.71
P/FCF ratio
0.00 0.00 13.62 10.79
P/Operating CF
52.44 (95.22) (176.27) (72.63)
P/B ratio
0.00 0.00 0.00 0.00
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
7.39 7.67 3.87 3.10
EV/EBITDA
45.79 0.00 7.53 5.78
EV/Operating CF
(244.38) (29.11) 9.41 7.70
EV/FCF
(24.83) (13.14) 15.10 12.35
Quick Ratio
3.20 2.29 2.20 2.18
Current Ratio
3.39 2.44 2.35 2.32
Net Debt/EBITDA
4.27 12.55 (10.33) 83.37
Debt/Assets
89.60% 91.11% 89.62% 90.10%
Debt/Equity
(17.61) (14.49) (12.65) (15.29)
Asset Turnover
0.34 0.30 0.75 0.79
Operating CF/Net income
1.55 21.02 0.25 (4.17)
Capex/Depreciation
(0.64) (0.11) (0.29) (48.24)
Interest Coverage
3.07 0.92 (1.29) 0.09
Research and Development Expense of Revenue
27.50% 37.01% 80.84% 47.47%
Selling, General and Administrative Expense of Revenue
22.36% 31.62% 58.83% 39.83%
Intangible Assets out of Total Assets
0.15 0.16 0.16 0.18
Share Based Compensation of Revenue
6.46% 8.59% 11.25% 9.21%
Graham Net Nets
(0.12) (0.14) (0.14) (0.16)
Graham Number
4.69 10.71 0.00 0.00
Earnings Yield
(0.60%) (3.42%) 11.57% 15.66%
Free Cash Flow Yield
(4.43%) (8.59%) 7.34% 9.27%
Revenue per Share
4.34 3.30 2.07 2.69
Operating CF per Share
1.56 (0.72) (0.43) (0.84)
Capex per Share
(0.09) (0.02) (0.03) (3.26)
Free Cash Flow per Share
1.47 (0.73) (0.46) (4.11)
Cash per Share
26.85 22.93 24.46 21.51
Shareholders Equity per Share
(1.99) (2.19) (2.58) (1.98)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
(1.99) (2.19) (2.58) (1.98)
Free Cash Flow
121.97 (60.39) (36.65) (322.50)
Working Capital
1,846.29 1,330.40 1,305.52 1,141.56
Capital Expenditures
(7.14) (1.35) (2.37) (256.19)
Net Current Asset Value
(798.48) (795.57) (830.13) (791.65)
EV/EBIT
59.35 0.00 7.72 7.10
Capex to Sales
0.02 0.01 0.01 1.21
Price to Operating Income
53.91 0.00 6.97 6.21
Other line items
Average Receivables
217.59 215.21 170.09 201.53
Average Payables
360.60 315.43 342.78 319.74
Average Inventory
62.71 48.62 51.42 44.18
Average Assets
2,942.32 2,762.25 2,301.90 2,242.97
Average Common Equity
(185.95) (183.11) (651.69) (605.05)

Fold the line items

Columns are period end dates